Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC172-2021 · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| NNC172-2021 low dose / Placebo | EXPERIMENTAL | - |
| NNC172-2021 high dose / Placebo | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| NNC172-2021 | DRUG | One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL |
| placebo | DRUG | One injection administered subcutaneously (s.c., under the skin) |
Inclusion Criteria: * Healthy male Japanese subjects defined as: Subjects born in Japan, time residing outside of Japan does not exceed 5 years, both parents and all 4 grandparents of Japanese descent * Body weight between 50 and 100 kg, both inclusive * Body mass index (BMI) between 18.0 and 30.0 ...
NNC172-2021 is an investigational small molecule being developed by Novo Nordisk for congenital bleeding disorders, including haemophilia A and haemophilia B. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
NNC172-2021 is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is in Phase 1 clinical development for congenital bleeding disorders.
NNC172-2021 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed for this asset.
NNC172-2021 has one completed Phase 1 clinical trial, NCT01555749, which investigated the pharmacokinetics of the drug at two dose levels in healthy Japanese subjects. The trial enrolled 8 male participants and was conducted in the United Kingdom.
No alternative names for NNC172-2021 have been identified. The drug is referred to solely by its development code NNC172-2021 in clinical trial records.